CONTENTS 3
SWOT Analysis . 7
Indonesia Pharmaceutical And Healthcare Industry SWOT 7
Indonesia Political SWOT 8
Indonesia Economic SWOT 9
Indonesia Business Environment SWOT . 10
Pharmaceutical Risk/Reward Ratings 11
Table: Asia Pacific Pharmaceutical And Healthcare Risk/Reward Ratings, Q312 . 11
Rewards 12
Risks 13
Market Summary – Indonesia 14
Regulatory Regime . 15
Pharmaceutical Advertising 16
Regional Harmonisation 17
Intellectual Property Issues 18
Counterfeit Drugs . 19
Generic Drug Legislation 21
Labelling Requirements 21
Free Trade Agreements. 22
Pricing Regime 23
Reimbursement Regime . 24
Industry Trends And Developments 25
Epidemiology . 25
Non-Communicable Diseases 26
Communicable Diseases 27
Public Health Developments . 28
Table: UN Millennium Development Goals For Indonesia 29
Healthcare System 30
Health Insurance 32
Healthcare System Reform 33
Research & Development 35
Herbal Medicines 36
Medical Devices 37
Industry Forecast Scenario 38
Overall Market Forecast 38
Table: Pharmaceutical Sales, 2008-2016 . 39
Healthcare Market Forecast . 40
Table: Overall Healthcare Expenditure, 2008-2016 . 42
Table: Government Healthcare Expenditure, 2008-2016 . 43
Table: Private Healthcare Expenditure, 2008-2016 . 43
Key Growth Factors – Macroeconomic 44
Table: Indonesia Economic Activity, 2011-2016 . 48
Prescription Drug Market Forecast . 49
Table: Prescription Drug Sales, 2008-2016 50
Patented Drug Market Forecast . 51
Table: Patented Drug Sales, 2008-2016 . 52
Generic Drug Market Forecast 53
Table: Generic Drug Sales, 2008-2016 55
OTC Medicine Market Forecast . 56
Table: OTC Medicine Sales, 2008-2016 . 57
Medical Device Market Forecast 58
Table: Medical Device Sales, 2008-2016 59
Pharmaceutical Trade Forecast . 60
Table: Pharmaceutical Trade, 2008-2016 63
Other Healthcare Data And Forecasts 64
Key Risks To BMI’s Forecast Scenario 64
Competitive Landscape . 66
Table: Top-10 Pharmaceutical Companies According To Market Capitalisation 67
Domestic Industry . 67
Foreign Industry . 69
Recent Pharmaceutical Sector Developments 69
Pharmaceutical Retail Sector 70
Company Profiles 72
Soho Group . 72
PT Kalbe Farma . 74
PT Bio Farma 76
Kimia Farma 78
Combiphar PT . 81
Sanofi . 83
Pfizer . 85
Novartis 87
GlaxoSmithKline . 89
Merck & Co 91
Bayer . 93
Demographic Outlook . 95
Table: Population By Age Group, 1990-2020 (‘000) 96
Table: Population By Age Group, 1990-2020 (% of total) 97
Table: Key Population Ratios, 1990-2020 98
Table: Rural/Urban Population Split, 1990-2020 98
BMI Methodology 99
How We Generate Our Pharmaceutical Industry Forecasts 99
Pharmaceutical Risk/Reward Ratings Methodology 100
Ratings Overview .100
Table: Pharmaceutical Business Environment Indicators 101
Weighting 102
Table: Weighting Of Components 102
Sources 102Table: Asia Pacific Pharmaceutical And Healthcare Risk/Reward Ratings, Q312 . 11
Table: UN Millennium Development Goals For Indonesia . 29
Table: Pharmaceutical Sales, 2008-2016 . 39
Table: Overall Healthcare Expenditure, 2008-2016 . 42
Table: Government Healthcare Expenditure, 2008-2016 . 43
Table: Private Healthcare Expenditure, 2008-2016 . 43
Table: Indonesia Economic Activity, 2011-2016 . 48
Table: Prescription Drug Sales, 2008-2016 . 50
Table: Patented Drug Sales, 2008-2016 . 52
Table: Generic Drug Sales, 2008-2016 . 55
Table: OTC Medicine Sales, 2008-2016 . 57
Table: Medical Device Sales, 2008-2016 . 59
Table: Pharmaceutical Trade, 2008-2016 . 63
Table: Top-10 Pharmaceutical Companies According To Market Capitalisation . 67
Table: Population By Age Group, 1990-2020 (‘000) . 96
Table: Population By Age Group, 1990-2020 (% of total) . 97
Table: Key Population Ratios, 1990-2020 . 98
Table: Rural/Urban Population Split, 1990-2020 . 98
Table: Pharmaceutical Business Environment Indicators .101
Table: Weighting Of Components .102